Genotypes affecting the pharmacokinetics of anticancer drugs

D Bertholee, JG Maring, ABP van Kuilenburg - Clinical pharmacokinetics, 2017 - Springer
Cancer treatment is becoming more and more individually based as a result of the large
inter-individual differences that exist in treatment outcome and toxicity when patients are …

Personalizing aromatase inhibitor therapy in patients with breast cancer

IS Hamadeh, JN Patel, S Rusin, AR Tan - Cancer treatment reviews, 2018 - Elsevier
Background Aromatase inhibitors are the mainstay of therapy for patients with hormone
receptor-positive breast cancer in both adjuvant and metastatic settings. Their use in clinical …

Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review

MC Barros-Oliveira, DR Costa-Silva… - Revista da Associação …, 2017 - SciELO Brasil
Aromatase inhibitors have emerged as an alternative endocrine therapy for the treatment of
hormone sensitive breast cancer in postmenopausal women. The use of third-generation …

[HTML][HTML] The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment

X Wu, H **
KJ Baatjes, M Conradie, JP Apffelstaedt… - Anti-Cancer Agents in …, 2017 - benthamdirect.com
Background: Genetics play a significant role in drug metabolism of endocrine therapy of
breast cancer. These aspects have been studied extensively in patients on tamoxifen, but …

Impact of CYP3A4 and CYP3A5 single nucleotide polymorphisms on anastrozole-associated adverse events among Malaysian breast cancer patients

MB Abubakar, HL Tan… - Asia Pacific Journal of …, 2019 - research.monash.edu
The catalytic activity of the cytochrome P450A (CYP3A4) enzyme is reportedly affected by
the presence of single nucleotide polymorphisms (SNPs), leading to inter-individual …